Sanofi US News

Sanofi launches R&D Consortium of industry and patient advocacy groups to accelerate medicines development

First-of-its-kind consortium brings together advocacy and industry organizations to address efficiencies across disease types that have the potential to speed the development of medicines for patients

Bridgewater, NJ, March 2, 2023. Sanofi has launched the Patient Advocacy Leaders and Drug Development Industry Network (Paladin) a first-of-its-kind Research and Development (R&D) Consortium, bringing together industry and US advocacy groups to accelerate medicines development regardless of disease.

Victoria DiBiaso

VP, Global Head Patient Informed Development & Health Value Translation at Sanofi

“We are thrilled to partner with an esteemed group of industry and patient advocacy organizations on this consortium, which was born out of our deep-rooted conviction for patient-centered R&D. Together, we have an opportunity to identify ways to reduce the time it takes to develop new medicines – bringing new treatments options to patients sooner and giving them hope for the future.”

Paladin aims to speed the pace of medicines development through jointly creating and building upon:

  • Common foundations that improve industry and advocacy R&D-focused collaborations;
  • Guidance and trainings for advocacy and industry representatives on how to implement patient- and caregiver-informed R&D approaches;
  • Measures to improve diversity in clinical trials through best-practice sharing across industry;
  • Awareness programming aimed at educating and connecting patients to clinical trials; and,
  • Knowledge-sharing across therapeutic areas to reduce silos and maximize learnings.

The consortium initially will focus on four priority pillars: consensus-driven standards, skills and training, clinical trial participation, and transparent solutions. To ensure the recommendations are co-developed to reflect solutions relevant to all stakeholders, each of the groups addressing the pillars will be co-led by, and composed of, representatives from industry and advocacy.

Sara Loud

Chief Executive Officer, Accelerated Cure Project

“While many collaborations already incorporate the patient voice, we can do more to speed the pace of medicines development to make a real impact for patients. This consortium’s vision is important as we work to establish consensus-driven guidelines, resources and competencies to optimize how we work together in our shared mission.”

Tufts University’s Center for the Study of Drug Development will lead project management and facilitation for the consortium.

Kenneth Getz

Executive Director and Research Professor, Tufts Center for the Study of Drug Development (CSDD), Tufts University School of Medicine

“This past decade, as the R&D pipeline continues to grow and target a wider range of diseases, there has been unprecedented demand for collaboration between patient advocacy groups and industry.  Through this new consortium, we have a unique and much-needed opportunity to optimize the process for developing new medical therapies.  We’re so grateful to be participating.”


Partner organizations

Sanofi is proud to partner with the following patient advocacy groups and industry organizations in launching the Consortium:

  • Accelerated Cure Project
  • Aimed Alliance
  • Allergy & Asthma Network
  • American Kidney Fund
  • Astellas
  • Black Health Matters
  • Bristol Myers Squibb
  • COPD Foundation
  • Merck, known as MSD outside of the United States and Canada
  • The Michael J. Fox Foundation for Parkinson’s Research
  • National Alliance for Caregiving
  • National Hemophilia Foundation
  • Opus Genetics
  • Sanofi
  • Susan G. Komen®
  • Tigerlily Foundation

The Consortium is open to industry, patient, and caregiver advocacy groups interested in helping to identify ways to transform the pace of medicines development. For more information, please contact


About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY


Media Relations
Evan Berland | 215.432.0234 |  


Sanofi Forward-Looking Statements 
This document contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2021. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.